Lumida
/GOSS
⌘K
Gossamer Bio Inc

Gossamer Bio Inc

GOSS
$10.73USD↓-5.81%-0.66 today

MARKET CAP

5.6B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$10 – $13

52W RANGE

$9
$310

AI Summary

Stalk
Sell NowMedium

GOSS remains in a Stage 4 decline with both long- and short-term downtrends intact. Price continues to trade below the 9, 21, 50, and 200 EMAs, with repeated rejections at those levels. The active Post-Capitulation pattern shows forced selling has exhausted but no base has formed, reinforcing a bearish medium-term stance. Short-term momentum and EMA rejection favor immediate downside participation, warranting a sell-now posture despite oversold context.

  • ↑NDA submission for seralutinib planned in Sep 2026 after positive FDA meeting
  • ↑Reacquiring full global rights to seralutinib maximizes future revenues
  • ↓Levered FCF of –$162.6 M and Q2 R&D spend of $26.4 M pressure liquidity
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Gossamer Bio, Inc. (NASDAQ:GOSS) is a biopharmaceutical company focused on developing therapies for inflammatory and fibrotic diseases. Its lead candidate, seralutinib, aims to address pulmonary arterial hypertension (PAH). The company has recently regained worldwide rights to seralutinib from Chiesi, positioning it for strategic control over its development and commercialization efforts. In the context of a strong focus on specialty medicines and the growing need for effective treatments in the rare diseases category, Gossamer Bio is a key player in advancing innovative therapeutic solutions.

Bull says

  • ↑NDA submission for seralutinib planned in Sep 2026 after positive FDA meeting
  • ↑Reacquiring full global rights to seralutinib maximizes future revenues
  • ↑Generated $9.2 M collaboration revenue, indicating partnership momentum
  • ↑Strong institutional ownership signals sector interest and potential outperformance
  • ↑HC Wainwright maintains Buy rating with $2.00 price target
  • ↑Managed debt levels support runway until key clinical milestones

Bear says

  • ↓Levered FCF of –$162.6 M and Q2 R&D spend of $26.4 M pressure liquidity
  • ↓Planned $250 M private placement risks dilution if milestones slip
  • ↓Negative earnings yield and poor profitability reflect weak returns
  • ↓Declining analyst revisions and momentum signal fading investor confidence
  • ↓Elevated short interest shows market skepticism and selling pressure
  • ↓Safety concerns (liver enzyme elevations, cough) could derail FDA approval

Investment themes with GOSS

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR
Julian Komar's Best Winners (Screen Results)↓ -0.50%

NVDA · GOOGL · AVGO

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-19-2026bullish

Transcript signals

Bull points

  • Our conviction in serolutinib has increased since the top line readout, not decreased. That conviction is based on a totality of evidence, consistent drug arm performance in ProSERA, confirmatory data from Tori, multi-compartment mechanistic evidence from the CT-FRI and the regulatory path we're advancing with the FDA.
  • We now have a confirmed Type B pre-NDA meeting and expect to submit the NDA in September of 2026.
  • Taken together with Phase III ProSERA data and the Phase II TORI data, we believe the overall evidence supports an NDA path for seraludinib.

Bear points

  • we engaged constructively with our convertible note holders to address the upcoming 2027 maturity.
Read full transcript analysis ›